Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 2.18M P/E 0.01 EPS this Y 86.10% Ern Qtrly Grth -
Income -20.42M Forward P/E -1.38 EPS next Y -6.30% 50D Avg Chg -61.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -99.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -100.00%
Recommedations 3.00 Quick Ratio 0.08 Shares Outstanding 6.18M 52W Low Chg 13.00%
Insider Own 0.02% ROA -81.09% Shares Float 5.56M Beta 0.23
Inst Own 0.94% ROE - Shares Shorted/Prior 614.25K/640.26K Price 2.53
Gross Margin - Profit Margin - Avg. Volume 624,959 Target Price -
Oper. Margin - Earnings Date - Volume 597,233 Change 1.61%
About Allarity Therapeutics, Inc.

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Allarity Therapeutics, Inc. News
03/27/24 Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
03/25/24 Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)
03/08/24 Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update
06:00 AM Allarity Therapeutics to Present at Biomarkers 2024
12/12/23 Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor
12/07/23 ALLR: Stenoparib Clinical Update
12/05/23 Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic
10/02/23 Allarity Therapeutics to Present at Biomarkers Europe 2023
09/14/23 Allarity Therapeutics Gaining Momentum? Hits Multiple Milestones Including Positive Publications In PLOS One And At ASCO, Positive Early Data From An Ongoing Clinical Trial, And External Partnering For Its DRP(R) Technology
08/30/23 PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib
07/31/23 Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics
07/24/23 Allarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives
07/12/23 ALLR: IXEMPRA Clinical Update
07/06/23 Allarity Therapeutics, Inc. Announces Pricing of $11 Million Public Offering
07/05/23 Initial Data from Allarity’s Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients
10:55 AM Allarity Therapeutics Announces Reverse Stock Split of Common Stock
06/27/23 Allarity Therapeutics Announces Clarification of Effective Date for Reverse Stock Split
06/20/23 Allarity Therapeutics Announces Adjournment of Special Meeting of Stockholders
05/30/23 First Prospective Clinical Validation of Allarity's DRP® Companion Diagnostic to be Presented at 2023 ASCO Annual Meeting
04/27/23 Allarity Therapeutics Accelerates Trial Enrollment To Bring FDA-Approved Breast Cancer Treatment To European Market - Interim Results Could Be Released In Second Half Of 2023
ALLR Chatroom

User Image Surfinthewaves Posted - 2 hours ago

$ALLR Anyone shorting this is out of their mind. When the news comes out the shorts will lose 10x what they are trying to make

User Image TradeWings Posted - 3 hours ago

$ALLR failure management has a nice surprise for shareholders

User Image TradeWings Posted - 3 hours ago

$ALLR everyone enjoy the reverse split. shareholders gonna get pounded in the ass raw by management when the stock price plummets >50%

User Image TradeWings Posted - 1 day ago

$ALLR they are now an ”all or nothing“ company. if stenoparib goes down they are done. not good.

User Image Stock_Titan Posted - 1 day ago

$ALLR Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer https://www.stocktitan.net/news/ALLR/allarity-therapeutics-makes-strategic-pivot-to-focus-solely-on-90z2m71btp11.html

User Image TradeWings Posted - 1 day ago

$ALLR Nowhere to go but down. Highly doubtful the cancer study results will be good.

User Image flynn_trader Posted - 2 days ago

$ALLR send her to 0.25

User Image Lysa_ja Posted - 2 days ago

$ALLR I just can't believe they are getting another extension. I thought this would have been in OTC by now.

User Image Thelionroarer Posted - 2 days ago

$ALLR what happened? ANYBODY KNOWS WHAT WE DONT KNOW

User Image Joe_088 Posted - 3 days ago

$ALLR now what we have one month to meet compliance but how?Rs???

User Image flyingpigs360 Posted - 3 days ago

$ALLR well sounds like a plan

User Image flyingpigs360 Posted - 3 days ago

$ALLR added

User Image Stock_Titan Posted - 3 days ago

$ALLR Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1) https://www.stocktitan.net/news/ALLR/allarity-therapeutics-receives-extension-from-nasdaq-hearings-panel-8nz3arh1mx3x.html

User Image bertbertybert Posted - 4 days ago

$ALLR bio roulette!!!

User Image Dollar_D Posted - 4 days ago

Sorry it's $ALLR

User Image GuruFocusOp Posted - 5 days ago

$ALLR there will be no reverse split now. the company has 50 million shelf offering. reverse split wont help to raise mony. cancer data read out in 4-6 weeks. sp will boost 1000% . then they will make an offering from shelf.

User Image ONLYPHARMS Posted - 5 days ago

$ALLR no vote on a reverse split yet? almost no institutional investment has to tell us something!!

User Image GuruFocusOp Posted - 5 days ago

$TCON any thought on $ALLR

User Image GuruFocusOp Posted - 5 days ago

$ALLR is the results coming this quarter or by june?? anyone also what is the market size of their treatment

User Image Jestofunk Posted - 6 days ago

$ALLR I said that at .50, it broke support then I said that at .40 and it’s broke that. I also said jokingly that .20-.25 would be the bottom and at this rate it will get there. Nothing to be bullish about here but not worth selling.

User Image ChiefOG Posted - 1 week ago

$ALLR 🧐

User Image Paulfrench Posted - 1 week ago

$ALLR In my opinion we are at the bottom, a little more effort and it will be time to enter....wait and see today's candle

User Image Bastard_Factory Posted - 1 week ago

$ALLR ..my avg. is 25 shares @ $37.68 - lol HALPPPPPP!

User Image Stocksrockman Posted - 1 week ago

$LIDR is working with $NVDA Crazy. Why is this not on everyone's list? It shouldn't be this low, and Monday this all changes. $ALLR really needs to hold here. We don't want to break support $ARBB same thing as allr. Mms keep driving these small caps down that have low volume.

User Image Jestofunk Posted - 1 week ago

$ALLR next you’ll wish you hadn’t bothered

User Image MarketMasterMind Posted - 1 week ago

$ALLR loading here 🤑Ⓜ️

User Image Surfinthewaves Posted - 1 week ago

$ALLR This will have a massive move like $OCEA and $CDIO

User Image Stevostock Posted - 2 weeks ago

$ALLR this stock is done!! I’m out. GL to the longs here.

User Image HabibiiAli Posted - 2 weeks ago

$ALLR Is today the day? $SOUN $NVDA 🤷🏼‍♂️

User Image Jestofunk Posted - 2 weeks ago

$ALLR Now the crypto market is here, the traditional stock market is dead, finished!!! Come to the wild west in trading because this shit is done! No SEC, No R/S, No delisting, No Halts, you get the gist…Come and make money!